资料显示，南京诺唯赞生物科技股份有限公司位于江苏省南京经济技术开发区科创路红枫科技园D2 栋，成立日期2012年3月16日，上市日期2021年11月15日，公司主营业务涉及围绕酶、抗原、抗体等功 能性蛋白及高分子有机材料进行技术研发和产品开发的生物科技企业,依托于自主建立的关键共性技术 平台,先后进入了生物试剂、体外诊断业务领域,并正在进行抗体药物的研发。主营业务收入构成为：生 物试剂81.86%，诊断试剂9.99%，耗材等材料3.15%，仪器设备2.96%，技术服务1.85%，其他0.18%。 12月23日，诺唯赞跌1.16%，成交额3259.78万元。两融数据显示，当日诺唯赞获融资买入额565.47万 元，融资偿还514.20万元，融资净买入51.28万元。截至12月23日，诺唯赞融资融券余额合计1.23亿元。 融资方面，诺唯赞当日融资买入565.47万元。当前融资余额1.23亿元，占流通市值的1.58%，融资余额 超过近一年90%分位水平，处于高位。 融券方面，诺唯赞12月23日融券偿还1012.00股，融券卖出4800.00股，按当日收盘价计算，卖出金额 9.43万元；融券余量9600.00股，融券余 ...

Company Overview - NuoVance Biotechnology Co., Ltd. focuses on the research and development of functional proteins and high molecular organic materials, including enzymes, antigens, and antibodies [1] - The main products include biological reagents, diagnostic reagents, equipment, technical services, and consumables [1] Financial Performance - For Q1 2025, the company reported revenue of 285 million yuan, a year-on-year decrease of 5.50% [1] - The net profit for the same period was 1.91 million yuan, down 63.39% year-on-year [1] - The gross profit margin stood at 69.40% [1] Shareholder Information - As of March 31, 2025, the number of shareholders increased to 8,397, up by 671 from the previous count [1] - The average market value of shares held by each shareholder is 352,800 yuan, with an average holding of 27,600 shares [1] Market Valuation - The latest closing price of NuoVance is 21.34 yuan, reflecting a decline of 2.33% [1] - The company's price-to-earnings (P/E) ratio is significantly negative at -396.61, with a price-to-book (P/B) ratio of 2.18 and a total market capitalization of 8.488 billion yuan [2]

Group 1 - The core viewpoint of the news is that NuoVaxan's stock has shown a slight increase, with a closing price of 22.49 yuan, reflecting a 1.90% rise and a market capitalization of 8.945 billion yuan [1] - As of March 31, 2025, NuoVaxan has 8,397 shareholders, an increase of 671 from the previous period, with an average holding value of 352,800 yuan and an average shareholding of 27,600 shares [1] - NuoVaxan's main business focuses on the research and development of functional proteins and high molecular organic materials, with key products including biological reagents, diagnostic reagents, equipment, technical services, and consumables [1] Group 2 - In the latest quarterly report for Q1 2025, NuoVaxan reported a revenue of 285 million yuan, representing a year-on-year decrease of 5.50%, and a net profit of 1.9099 million yuan, down 63.39% year-on-year, with a gross profit margin of 69.40% [1] - The company's price-to-earnings (PE) ratio is significantly negative at -417.99 (TTM) and -494.37 (static), while the industry average PE is 48.90 (TTM) and 47.00 (static) [2] - The market valuation of NuoVaxan is 8.945 billion yuan, with a price-to-book ratio of 2.29, compared to the industry median of 2.40 [2]